Structural optimization of 4-(2-chlorophenyl)-9-methyl-6H-thieno [3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepines as antagonists for platelet activating factor: Pharmacological contribution of substituents at the 2- and 6-positions of a condensed ring system

European Journal of Medicinal Chemistry

Volumn 31, Issue 9, 1996, Pages 683-692

  Kawakami, Y ^a   Kitani, H ^a   Yuasa, S ^a   Abe, M ^a   Moriwaki, M ^a   Kagoshima, M ^a   Terasawa, M ^a   Tahara, T ^a  

^a Yoshitomi Pharmaceutical Industries Ltd   (Japan)

Author keywords

PAF antagonist; Platelet activating factor (PAF); Structure activity relationship; Thienotriazolodiazepine; Y 24180

Indexed keywords

ISRAPAFANT; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IN VITRO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MORTALITY; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION;

EID: 0029828237     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/0223-5234(96)85877-6     Document Type: Article

References (29)

1. 1 Lynch JM, Lontner GZ, Betz SJ, Henson PM (1979) J Immunol 123, 1219-1226
2. 2 Lontner GZ, Lynch JM, Betz ST, Henson PM (1980) J Immunol 124, 676-684
3. 3 Chignard M, Le Couedic JP, Ten Cl M, Vargaftig BB, Benveniste J (1979) Nature 179, 799-800
4. 4 Demopoulos CA, Pinckard RN, Hanahan, DJ (1979) J Biol Chem, 254, 9355-9358.
5. 5 Morely J, Page CP, Paul W (1983) Br J. Pharmacol 80, 503-509
6. 6 Stimler NP, Bloor CM, Hugli TE, Wykle RL, MaCall CE, O'Flaherty JT (1981) Am J Pathol 105, 64-69
7. 7 Wedmore CV, Williams JJ (1981) Nature 289, 646-650
8. 8 Terashita Z, Imura Y, Nishikawa K, Sumida S (1985) Eur J Pharmacol 109, 257-261
9. 9 Kornecki E, Ehrlich YH, Lexon RH (1984) Science 226, 1454
10. 10 Mikashima H, Takehara S, Muramoto Y, Khomaru T, Terasawa M, Tahara T, Maruyama Y (1987) Jpn J Pharmacol 44, 387-391
11. 11 Terasawa M, Mikashima H, Tahara T, Maruyama Y (1987) Jpn J Pharmacol 44, 381-386
12. 12 Tahara T, Mikashima H, Terasawa M, Maruyama Y (1987) Chem Pharm Bull Jpn 35, 2119-2121.
13. 13 Moriwaki M, Abe M, Yuasa S, Naka Y, Terasawa M, Mikashima H, Tahara T (1989) In: 3rd International Conference PAF and Structurally Related Alkyl Ether Lipids, Abstracts 11, 92
14. 14 Asals-Stenzel J, Muacevic G, Weber KH (1987) J Pharmacol Exp Therap 241, 974-981
15. 15 Miyazawa S, Okano K, Shimomura N et al (1991) Chem Pharm Bull Jpn 39, 3215-3220
16. 16 Berliner E (1949) Org React 5, 229-289
17. 17 Ratcliffe R, Rodehorst R (1970) J Org Chem 35, 4000-4002
18. 18 Anelli PL, Biffi C, Montanari F, Quici S (1987) J Org Chem 52, 2559-2562
19. 19 Gewald K, Schinke E, Bottcher N (1966) Chem Ber 99, 94-100
20. 20 Nakanishi M, Tahara T, Araki K, Shiroki M, Tsumagari T, Takigawa Y (1973) J Med Chem 16, 214-219.
21. 21 Tahara T, Araki K, Shiroki M, Matsuo H, Munakata T (1978) Arzneim-Forsch Drug Res 28, 1153-1158
22. 22 Weber KH, Heuer H (1989) Int Arch Appl Immunol 88, 82-87
23. 23 Tahara T, Moriwaki M, Abe M, Terasawa M (1989) Jpn Kokai Tokkyo Koho JP01/79186; Chem Abstr 110, 192804z
24. 24 Moriwaki M, Tanaka H, Terasawa M, Tahara T (1990) Jpn Kokai Tokkyo Koho JP 02/256681; Chem Abstr 112, 77237w
25. 25 Tahara T, Moriwaki M, Abe M, Yuasa S (1989) Jpn Kokai Tokkyo Koho JP 01/156982; Chem Abstr 109, 211096
26. 26 Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T (1990) Prostaglandins 40, 571-583
27. 27 Young JM, Maloney PJ, Jubb SN, Clark JS (1985) Prostaglandines 30, 545-551
28. 28 Valone FH, Coles E, Reinhold VR, Goetzl EJ (1982) J Immunol 129, 1637-1641
29. 29 MöhlerH, Okada T (1977) Life Sci 20, 2101-2110